Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study

Scand J Gastroenterol. 1995 Sep;30(9):839-46. doi: 10.3109/00365529509101589.

Abstract

Background: Omeprazole is effective in the treatment of reflux oesophagitis, and it is important to determine the lower dose limit with still appropriate clinical efficacy.

Methods: Patients with endoscopic oesophagitis grade 1-4 (N = 220) were randomized to double-blind treatment with 20 mg or 40 mg omeprazole daily for 4-8 weeks. Those healed after this initial treatment phase were re-randomized to double-blind treatment with 20 mg omeprazole daily (n = 67), 10 mg omeprazole daily (n = 68), or placebo (n = 33) for 6 months. Remission was defined as the absence of any endoscopic sign of oesophagitis.

Results: Healing rates were increased with 40 mg omeprazole, the therapeutic gain compared with the 20-mg dose being 15% after 4 and 8 weeks. The proportion of patients in remission after 6 months was 59% with 20 mg omeprazole, 35% with 10 mg omeprazole, and 0% with placebo.

Conclusion: Maintenance treatment with 10 mg omeprazole can prevent recurrence of oesophagitis in about one-third of patients with all grades of oesophagitis, and 20 mg omeprazole in about twice as many.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Ulcer Agents / administration & dosage*
  • Anti-Ulcer Agents / therapeutic use
  • Confidence Intervals
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Esophagitis, Peptic / drug therapy*
  • Esophagitis, Peptic / etiology
  • Esophagitis, Peptic / physiopathology
  • Female
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Omeprazole / administration & dosage*
  • Omeprazole / therapeutic use
  • Recurrence
  • Regression Analysis
  • Treatment Outcome

Substances

  • Anti-Ulcer Agents
  • Omeprazole